97 related articles for article (PubMed ID: 19064953)
1. Prevention of hearing loss in children receiving cisplatin chemotherapy.
Freyer DR; Sung L; Reaman GH
J Clin Oncol; 2009 Jan; 27(2):317-8; author reply 318-9. PubMed ID: 19064953
[No Abstract] [Full Text] [Related]
2. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
3. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Fouladi M; Chintagumpala M; Ashley D; Kellie S; Gururangan S; Hassall T; Gronewold L; Stewart CF; Wallace D; Broniscer A; Hale GA; Kasow KA; Merchant TE; Morris B; Krasin M; Kun LE; Boyett JM; Gajjar A
J Clin Oncol; 2008 Aug; 26(22):3749-55. PubMed ID: 18669462
[TBL] [Abstract][Full Text] [Related]
4. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
[TBL] [Abstract][Full Text] [Related]
5. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
Hayek M; Srinivasan A
Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
[No Abstract] [Full Text] [Related]
6. Hearing loss in pediatric cancer survivors treated with cisplatin.
Knight K
Oncology (Williston Park); 2008 Apr; 22(4 Suppl Nurse Ed):35-7. PubMed ID: 19856560
[No Abstract] [Full Text] [Related]
7. Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
Sullivan MJ
Cancer; 2009 Dec; 115(24):5623-6. PubMed ID: 19813276
[No Abstract] [Full Text] [Related]
8. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
[TBL] [Abstract][Full Text] [Related]
9. [Protective effect of fosfomycin on cisplatin-induced ototoxicity--a case report].
Murao S
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1172-4. PubMed ID: 3566310
[No Abstract] [Full Text] [Related]
10. Future opportunities in preventing cisplatin induced ototoxicity.
van den Berg JH; Beijnen JH; Balm AJ; Schellens JH
Cancer Treat Rev; 2006 Aug; 32(5):390-7. PubMed ID: 16781082
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cisplatin-induced hearing-loss by sodium thiosulfate in medulloblastoma.
Harao T; Yamada A; Kinoshita M; Kamimura S; Moritake H
Pediatr Int; 2020 Oct; 62(10):1204-1206. PubMed ID: 32989850
[No Abstract] [Full Text] [Related]
13. [Effects of high-doses cisplatin on the auditory function in children].
Stura M; Tarantino V; Perin GP; Dallorso S; Haupt R
Minerva Pediatr; 1986 Nov; 38(22):1069-74. PubMed ID: 3807851
[No Abstract] [Full Text] [Related]
14. Hearing loss in children receiving cisplatin chemotherapy.
McHaney VA; Thibadoux G; Hayes FA; Green AA
J Pediatr; 1983 Feb; 102(2):314-7. PubMed ID: 6681630
[No Abstract] [Full Text] [Related]
15. [Prevention and treatment of toxic and adverse effects of cisplatin].
Deng C; Huang R; Lian L; Song H
Zhonghua Fu Chan Ke Za Zhi; 1995 Jun; 30(6):376-9. PubMed ID: 7555375
[No Abstract] [Full Text] [Related]
16. Effects of cisplatin on olfactory function in cancer patients.
Yakirevitch A; Talmi YP; Baram Y; Weitzen R; Pfeffer MR
Br J Cancer; 2005 May; 92(9):1611-3. PubMed ID: 15827551
[TBL] [Abstract][Full Text] [Related]
17. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
Lee JW; Pussegoda K; Rassekh SR; Monzon JG; Liu G; Hwang S; Bhavsar AP; Pritchard S; Ross CJ; Amstutz U; Carleton BC;
Ther Drug Monit; 2016 Aug; 38(4):423-31. PubMed ID: 26960170
[TBL] [Abstract][Full Text] [Related]
18. Changes to spontaneous otoacoustic emissions (SOAEs) due to cisplatin administration.
Kuroda T; Chida E; Kashiwamura M; Matsumura M; Fukuda S
Int J Audiol; 2008 Nov; 47(11):695-701. PubMed ID: 19031228
[TBL] [Abstract][Full Text] [Related]
19. Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.
Hazlitt RA; Min J; Zuo J
J Med Chem; 2018 Jul; 61(13):5512-5524. PubMed ID: 29361217
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen.
Arora R; Thakur JS; Azad RK; Mohindroo NK; Sharma DR; Seam RK
Indian J Cancer; 2009; 46(4):311-7. PubMed ID: 19749461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
